Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.17 EUR
Change Today 0.00 / 0.00%
Volume 0.0
LJHB On Other Exchanges
Hong Kong
As of 4:00 PM 10/16/14 All times are local (Market data is delayed by at least 15 minutes).

lijun intl pharmacetl hldg (LJHB) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

lijun intl pharmacetl hldg (LJHB) Related Businessweek News

No Related Businessweek News Found

lijun intl pharmacetl hldg (LJHB) Details

Lijun International Pharmaceutical (Holding) Co., Ltd., an investment holding company, researches, develops, manufactures, and sells pharmaceutical products to hospitals and distributors primarily in Mainland China. It offers sodium chloride, metronidazole and glucose, and compound amino acid (l8AA) injections. The company is also involved in research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; and food and beverages business. It offers intravenous infusion solutions under the Shimen brand name. Lijun International Pharmaceutical (Holding) Co., Ltd. is headquartered in Wanchai, Hong Kong.

3,600 Employees
Last Reported Date: 04/15/15

lijun intl pharmacetl hldg (LJHB) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $7.4M
Executive Director
Total Annual Compensation: $1.2M
Compensation as of Fiscal Year 2013.

lijun intl pharmacetl hldg (LJHB) Key Developments

Lijun International Pharmaceutical (Holding) Co Ltd. Reports Consolidated Cash Flow Results for the Year Ended December 31, 2014

Lijun International Pharmaceutical (Holding) Co Ltd. reported consolidated cash flow results for the year ended December 31, 2014. For the period, net cash generated from operating activities was HKD 307,607,000 against HKD 597,922,000 a year ago. Purchase of property, plant and equipment was HKD 767,488,000 against HKD 758,529,000 a year ago. Purchase of intangible assets was HKD 24,853,000 against HKD 6,411,000 a year ago.

Lijun International Pharmaceutical (Holding) Co., Ltd. Announces Executive Changes with Effect from 1 April 2015

The board of directors of Lijun International Pharmaceutical (Holding) Co., Ltd. announced that Mr. Chan Ka Kit has resigned as the Chief Financial Officer and Company Secretary of the company with effect from 1 April 2015 in order to pursue other career opportunities. Mr. Chan has also ceased to act as an authorised representative of the company under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. Mr. Chan has confirmed that he has no disagreement with the Board and there are no matters that need to be brought to the attention of the Stock Exchange or/and the shareholders of the company in relation to his resignation. The board also announced that Mr. Chow Hing Yeung has been appointed as the Chief Financial Officer, Company Secretary and the Authorised Representative of the company with effect from 1 April 2015. Mr. Chow is a member of the Hong Kong Institute of Certified Public Accountants. Mr. Chow obtained a Bachelors degree of Business Administration from the Chinese University of Hong Kong. He has more than 15 years of experience in areas of auditing, accounting and financial management. Mr. Chow was the Chief Financial Officer and Company Secretary of the company during the period from 26 August 2011 to 10 May 2013.

Lijun International Pharmaceutical (Holding) Co Ltd. Omits Final Dividend and Approves Special Dividend for the Year Ended December 31, 2014 Payable on or About May 22, 2015

Lijun International Pharmaceutical (Holding) Co Ltd. announced that on March 27, 2015, a special dividend of HKD 0.172 per ordinary share, amounting to a total dividend of HKD 510,587,000 has been determined by the directors of the company to be paid out of the company's retained earnings and share premium account. Pursuant to Section 34 of the Cayman Companies Law (2003 Revision) and the Articles of Association of the Company, balance in share premium account of the company is available for distribution to shareholders subject to a solvency test on the company. The company proposed zero final dividend per share for the year ended December 31, 2014 against HKD 0.02 per share last year, which, together with the interim dividend and the special dividend, will result in total dividends of HKD 0.232 per share for the year 2014 against HKD 0.04 per share last year. In order to qualify for the special dividend approved at the extraordinary general meeting on October 10, 2014 and declared by the board on March 27, 2015, all properly completed transfer forms, accompanied by the relevant share certificates, must be lodged with the company's branch share registrar and transfer office in Hong Kong, Computershare Hong Kong Investor Services Limited by no later than 4:30 p.m., May 12, 2015 which is the record date for the special dividend. The special dividend is expected to be paid on or about May 22, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LJHB:GR €0.17 EUR 0.00

LJHB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LJHB.
View Industry Companies

Industry Analysis


Industry Average

Valuation LJHB Industry Range
Price/Earnings 22.4x
Price/Sales -- Not Meaningful
Price/Book 3.4x
Price/Cash Flow 18.3x
TEV/Sales 4.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIJUN INTL PHARMACETL HLDG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at